Annual report [Section 13 and 15(d), not S-K Item 405]

Summary of Significant Accounting Policies (Tables)

v3.25.1
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2024
Summary of Significant Accounting Policies  
Schedule of significant expense categories

    

Year Ended

December 31,

December 31,

    

2024

2023

Operating expenses:

Clinical

$

1,153,345

$

112,196

Chemical, manufacturing and controls

710,055

312,691

Research and preclinical

505,750

267,803

Regulatory

20,065

186,395

Other research and development costs

1,141,698

848,993

Total research and development

3,530,913

1,728,078

General and administrative expenses

8,696,335

3,718,841

Total operating expenses

$

12,227,248

$

5,446,919

Interest expense (income), net

92,192

(150,904)

Exchange loss, net

 

30,787

 

Net loss before income taxes

$

12,350,227

$

5,296,015